Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

NCT03060447 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03060447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
May 9, 2017
Completion date
February 13, 2020
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection